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Structural insights into the ene-reductase
synthesis of profens†
J. Waller,‡a H. S. Toogood,‡a V. Karuppiah,a N. J. W. Rattray,a D. J. Mansell,a D. Leys,a
J. M. Gardiner, a A. Fryszkowska,§b S. T. Ahmed,a R. Bandichhor,c G. P. Reddyc and
N. S. Scrutton *a
Reduction of double bonds of α,β-unsaturated carboxylic acids and esters by ene-reductases remains
challenging and it typically requires activation by a second electron-withdrawing moiety, such as a halide
or second carboxylate group. We showed that profen precursors, 2-arylpropenoic acids and their esters,
were eﬃciently reduced by Old Yellow Enzymes (OYEs). The XenA and GYE enzymes showed activity
towards acids, while a wider range of enzymes were active towards the equivalent methyl esters.
Comparative co-crystal structural analysis of profen-bound OYEs highlighted key interactions important
in determining substrate binding in a catalytically active conformation. The general utility of ene
reductases for the synthesis of (R)-profens was established and this work will now drive future muta-
genesis studies to screen for the production of pharmaceutically-active (S)-profens.
Introduction
Biocatalysis is an important tool in sustainable chemicals pro-
duction by enabling mild reaction conditions and often high
stereo-, regio- and enantio-selectivity.1 The ene reductases
(ERs) are identified as important biocatalysts for asymmetric
reduction of activated CvC bonds.2 The flavin-containing
NAD(P)H-dependent Old Yellow Enzyme (OYE) family of
enzymes have been studied extensively for their biocatalytic
potential due to their ability to catalyse the asymmetric
reduction of activated CvC bonds to generate up to two stereo-
genic centres. e.g. ref. 2a and 3. Typical activating groups
include keto, aldehyde and nitro-moieties,2a in contrast to
α,β-unsaturated mono-carboxylic acids and monoesters, which
are typically poor substrates. In the latter case, reduction
requires an additional electron-withdrawing group(s) conju-
gated to the double bond.3b,4
Profens (2-arylpropanoic acids), such as naproxen ((S)-1), are
important class of non-steroidal anti-inflammatory drugs
(NSAIDS), widely used to treat pain and inflammatory diseases
such as osteo- and rheumatoid arthritis.5 There has been inter-
est in developing new routes to the enantiomerically-pure 2-aryl-
propanoic acids. e.g. ref. 6. Recently, the use of ERs in the chemo-
enzymatic synthesis of (R)-flurbiprofen (2) has been demon-
strated,7 where the asymmetric CvC reduction of the precursor
was achieved by the OYE YqjM from Bacillus subtilis. Several
alternative biocatalytic strategies were proposed such as (i) self-
suﬃcient H-borrowing cascades in which OYEs coupled to alde-
hyde dehydrogenases to convert α,β-unsaturated aldehydes to a
diverse range of (chiral/achiral) α-substituted carboxylic acids8
or (ii) use of FMN and ferredoxin [4Fe–4S]-dependent clostridial
enoate reductases, which can reduce weakly activated enoates.9
Here, we explored the reaction scope of ene reductases from
OYEs and other enzyme classes2a in profen synthesis from
profen precusors (Scheme 1b and c). The experimental data
was underpinned by the co-crystal structures of two oxidised
OYEs XenA (from Pseudomonas putida)10 and NerA (from
Agrobacterium radiobacter)11 with 2-phenylacrylic acid 5b. This
revealed the active site structural features crucial for substrate
binding that will drive future structure-driven evolution of the
enzymes in the synthesis of non-steroidal anti-inflammatory
profens and related compounds.
Results and discussion
General
We studied the reduction of α,β-unsaturated carboxylic acids
5a–c by eight OYE family members12 and a flavin-independent,
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medium chain reductase, NtDBR, from Nicotiana tabacum.13 A
prior study showed only a few ene-reductases were capable of
reducing 5b.14 We ran 6 OYE classical subclass members:
PETNR,15 OYE2 and OYE3,16 GYE,17 LeOPR1,18 NerA19 as well
as 2 thermophilic-like members XenA,20 and TOYE21 (ESI
Table S1† and Table 1 legends). These two subclasses diﬀer in
sequence length, key residue substitutions, oligomeric state
and display distinct structural motifs.2 Thermophilic OYEs
have tetrameric or higher oligomeric states, shorter sequence
lengths due to the loss of some surface loops and contain a
highly-conserved, arginine finger involved in substrate
binding.12 Each enzyme contained either a N- or C-terminal
His6-tag (C-His8 for PETNR) to enable rapid protein
purification.
Enzymatic activity
Steady-state turnover reactions were performed with each puri-
fied enzyme using the known substrates ketoisophorone,
2-cyclohexen-1-one and nitrocyclohexene to check for native
activity (ESI Table S1†). The specific activities of PETNR and
NtDBR matched literature values, while TOYE and XenA
showed a 40% and 30% reduction in activity, respectively.
Subsequently two naproxen (1) precursors 2-(6-methoxy-
naphthalen-2-yl)acrylic acid 5a and its methyl ester 3a were
tested (Table 1). Carboxylic acid products were converted into
the equivalent methyl esters using trimethylsilyl diazomethane
prioir the GC analysis (ESI Fig. 1†). Out of 9 ene-reductases
tested with substrate 5a only XenA and GYE were active,
showing 94–95% conversion to 1a. Subsequently, we ran the
reactions on 50 mg-scale with both XenA and GYE to
isolate the product by preparative HPLC to confirm its struc-
ture by LCMS, 1H NMR and chiral HPLC (ESI Fig. 2 and 3†).
Unfortunately both XenA and GYE generated (R)-1a with high
enantiopurity (>99% ee; ESI Fig. 4 and 5†), rather than the
pharmacologically active (S)-enantiomer.
Six enzymes displayed activity towards methyl ester 3a to
give (R)-4a (Table 1 and ESI Fig. 6†). The highest conversion
(54%) was obtained with XenA, while GYE, LeOPR1 and TOYE
were 2–3-fold less active. PETNR and NerA showed <10% con-
version. No (S)-selective enzyme was identified in this study.
OYEs XenA and GYE were subsequently tested with 2-(4-propyl-
phenyl)acrylic acid 5b and 2-phenylacrylic acid 5c. Low con-
versions were obtained with substrate 5b (Table 1), as deter-
mined previously with GYE in previous studies.14 No activity
was detected with LeOPR1, however earlier work showed a
slight (15% conversion) reaction with 5b.14 In contrast, XenA
and YqjM quantitatively reduced 2-phenylpropenoic acid 5b to
5c, with moderate conversion (44%) obtained with GYE (Table 1;
ESI Fig. 7†). Reactions with the best enzymes were performed on
a 50 mg-scale and the products were isolated by preparative
HPLC. Structural identity was confirmed by 1H NMR and
Scheme 1 (A) Profens: (S)-naproxen 1a, (R)-ﬂurbiprofen 2. (B) and (C)
Proposed ene-reductase-catalysed steps in the chemoenzymatic syn-
thesis of profens.
Table 1 Biotransformations of ene-reductases with profens 3b and
5a–c
Substrate Product Enzyme Conv.a (%) eeb (%)
3a XenA 57 >99 (R)
GYE 24 >99 (R)
LeOPR1 21 >99 (R)
TOYE 17 >99 (R)
PETNR 9 >99 (R)
NerA 3 >99 (R)
5a XenA 94 >99 (R)
GYE 95 >99 (R)
5b XenA 97c >99 (R)
GYE 44b >99 (R)
YqjMd 95d (ref. 7) >99 (R)
5c XenA 7c,d N/D
GYE 27c,d N/D
Reactions (1 mL) were performed in buﬀer (K2HPO4/KH2PO4 pH
7.5) containing the alkene (5 mM in 100% DMF), NADP+ (10 μM),
D-glucose (15 mM), glucose dehydrogenase (GDH; 10 U) and enzyme
(2 μM). Reactions were shaken at 30 °C for 24 h at 130 rpm. a Conv. =
conversions. Quantitative analysis was performed on reactions
extracted with ethyl acetate (0.9 mL) and derivatised with trimethylsilyl
diazomethane to produce the respective methyl ester. Samples were
analysed by GC using a ZB-semi volatiles column. b Enantiomeric
excess was determined on reactions diluted 10-fold with acetonitrile,
and analysed by HPLC using a Chiralpak AS-RH or Chiralpak AD-H
column for 1a or 4a, respectively. cReactions were performed in
K2HPO4/KH2PO4 buﬀer pH 6.0.
d Reactions were performed in 20 mM
phosphate buﬀer containing 2-methyl-tetrahydrofuran. OYEs tested
were PETNR = pentaerythritol tetranitrate reductase from Enterobacter
cloacae PB2; LeOPR1 = 12-oxophytodienoate reductase 1 from Solanum
lycopersicum; NerA = GTN reductase from Agrobacterium radiobacter;
OYE2 from Saccharomyces cerevisiae; OYE3 from Saccharomyces cerevi-
siae; GYE from Gluconobacter oxydans; XenA = xenobiotic reductase
from Pseudomonas putida; and TOYE = thermophilic Old Yellow
Enzyme from Thermoanaerobacter pseudethanolicus E39. Due to quan-
tity limitations of substrates 5a to 5c, they were only tested with OYEs
active towards other profen precursors.
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UHPLC-MS (ESI Fig. 8–10†). In comparison, prior studies of
the reduction of the methyl ester derivative of 3b by the OYE
ClER from Clavispora lusitaniae showed no activity.22 We tested
all the OYEs and NtDBR with (Z)-but-2-enoic acid and
methacrylic acid, but no activity was detected.
Structures of XenA and NerA bound to 2-phenylacrylic acid 5b
We performed sequence (Fig. 1) and structural (Table 2 and
Fig. 2) comparisons of XenA, NerA and other OYEs to explain
the diﬀerences in their reactivity towards the substrates 3a and
5a–c. While XenA and YqjM belong to the thermophilic-like
class, GYE is a classical OYE, indicating that the activity
towards profens is not restricted to a single subclass of OYEs.
We determined the co-crystal structures of XenA and NerA with
2-phenylacrylic acid 5b, the latter inactive against this sub-
strate. In spite of extensive crystallisation trials, no co-crystal
structure of XenA or NerA could be obtained with naproxen
precursor 5a due to poor compound solubility in crystallisation
solution. The data summary and refinement parameters for
these structures are listed in Table 2. The structures enabled a
comparison of substrate binding modes in both active and
inactive conformations.
The overall crystal structure of XenA (Fig. 2A) is similar to
the ‘thermophilic-like’ OYEs namely GkOYE from Geobacillus
kaustophilus24 (rmsd of 1.1 Å over 333 residues), YqjM12 (rmsd
of 1.1 Å over 332 residues), TsOYE from Thermus scotoductus
SA-0125 (rmsd of 1.2 Å over 348 residues), and TOYE from
Thermoanaerobacter pseudethanolicus E3921 (rmsd of 1.2 Å over
331 residues). In this OYE subclass the functional unit is a
homodimer, composed of two sets of monomeric active sites
with the addition of a highly conserved ‘arginine finger’
residue (R333 in TOYE; Fig. 1) from an adjacent monomer.21
In the case of XenA, this conserved arginine is replaced by a
tryptophan (W358; Fig. 2B). Comparisons with our previously
determined XenA structures bound to nicotinamide biomime-
tics,3b showed that the majority of the active site residues were
relatively unchanged in position. The exception was W358 that
was oriented away from the FMN, likely due to the presence of
the bulky ligand 5b (Fig. 2B). Interestingly, the position of
ligand 5b in XenA is roughly equivalent to the location of
NADPH mimics in other crystal structures.3b
The aromatic ring and unsaturated carbons of 5b are
oriented parallel and facing the si-face of the non-covalently
bound isoalloxazine ring of FMN (Fig. 2B). The carbonyl
oxygen and hydroxyl group are positioned to enable hydrogen
bonds with residue atoms H178 NE, H181 ND and Y183 OH
Fig. 1 Sequence alignment, using PROMALS3D,23 showing selected regions covering the active site residues of ‘classical’ and ‘thermophilic-like’
class of OYEs. Active site residues are highlighted in green and red for classical and thermophilic-like OYEs respectively. Residue numbers are dis-
played for NerA and XenA.
Table 2 X-ray data collection and reﬁnement statistics for the co-
crystal structures of XenA-5b and NerA-5b
Parameters XenA-5b (PDB 5N6Q) NerA-5b (PDB 5N6G)
Data collection
Space group P22121 P212121
Unit cell dimensions a = 57.39 Å,
b = 84.04,
a = 60.09 Å,
b = 69.16,
c = 155.97 Å;
α = β = γ = 90°
c = 91.89 Å;
α = β = γ = 90°
X-ray source DLSa-I24 DLSa-I03
Wavelength (Å) 0.96862 0.97625
Resolution range (Å) 77.99–2.20
(2.27–2.20)b
91.89–1.58
(1.62–1.58)b
Multiplicity 3.5 (3.5) 6.3 (6.2)
I/σI 5.6 (1.8) 12.1 (1.5)
Completeness (%) 98.4 (98.6) 99 (98.1)
Rmerge 0.195 (0.982) 0.088(1.14)
Rmeas 0.230 (1.153) 0.106 (1.357)
Rpim 0.118 (0.592) 0.042 (0.535)
CC1/2 0.982 (0.514) 0.998 (0.543)
Total observations 133 897 (11 604) 332 942 (23 776)
Total unique
observations
38 419 (3290) 52 569 (3809)
Wilson B factor 18.269 14.638
Refinement
R-work 0.1658 0.1404
R-free 0.2254 0.1641
RMS (bonds) 0.009 0.008
RMS (angles) 0.94 0.97
Average B-factor 25.6 23.9
Ramachandran plot statistics (%)
Favored 95.46 97.82
Allowed 4.26 1.91
Outliers 0.28 0.27
aDiamond light source. b Values in parentheses correspond to the
higher resolution shell.
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(Fig. 2B). Additionally, the carbonyl oxygen of 5b is 3.1 and
3.2 Å away from N3 and O2 atoms of FMN, respectively.
Finally, the aromatic ring of 5b is stabilised by hydrogen
bonding with residue Y27. Given that the Cα and Cβ of the
substrate is only 3.8 Å from the N5 atom of FMN, this suggests
that the structure represents an active confirmation for CvC
reduction.
The overall co-crystal structure of NerA (Fig. 2C), bound to
5b, is similar to the ‘classical’ OYEs such as PETNR26 (rmsd of
1.3 Å over 354 residues), MR from Pseudomonas putida M1027
(rmsd of 1.3 Å over 354 residues), NCR from Zymomonas
mobilis28 (rmsd of 1.3 Å over 350 residues), previous NerA
structure29 and SYE1 from Shewanella oneidensis30 (rmsd of
1.6 Å over 355 residues). Similar to the XenA-5b structure, the
monomeric NerA-5b complex looks similar to its respective
apo structure.19 The residues lining the active site (Fig. 2D) are
in a similar position as in the apo structure.19
As previously noted19 the long loop β3, which partially caps
the active site, is highly flexible as measured by the higher
B-factors and the observation of weaker electron density for
this region. Compared to the apo-structure, the loop β3 in the
phenylacrylic acid-bound structure has significantly moved
away from the active site (Fig. 2E).
This rearrangement has caused the side chain of residue
T129 to be shifted closer to the aromatic ring of phenylacrylic
acid 5b (Fig. 2D), a position occupied by F139 in the apo-struc-
ture. However the density for the side chain of Y129 indicates
it likely occupies at least two diﬀerent conformations, the
second position located further away from the active site.
Phenylacrylic acid 5b is bound to the active site of NerA
with the carbonyl oxygen and hydroxyl group position similar
to the XenA-5b complex. As expected, the carbonyl oxygen of
5b forms hydrogen bonds with catalytic residues H178, N181
and Y183. Also, the hydroxyl moiety forms a hydrogen bond
with a nearby water molecule. More importantly, the orien-
tation of unsaturated carbons and the aromatic ring of 5b
diﬀer significantly from XenA-5b complex (Fig. 2F). This part
of the molecule has flipped upwards and twisted away from
the N5 atom of FMN, causing the aromatic ring of 5b to no
longer be parallel to the isoalloxazine ring of FMN. This alter-
nate orientation results in the formation of hydrogen bonds
between the methylene group of 5b and OG atom of T125, and
Fig. 2 Structural comparisons of the co-crystal structures of XenA-5b and NerA-5b. (A) Overall structure of XenA, with the amino acids shown as
ribbons with FMN (coral) and 5b (purple) as sticks. (B) Active site of XenA bound to ligand 5b. The side chains of residues that are up to 4 Å distance
surrounding 5b are displayed. Trp358 in XenA, which is from the adjacent monomer, is labelled with an asterisk. The oxygen, nitrogen and phospho-
rous atoms are coloured red, blue and magenta respectively. The Fo–Fc omit maps (blue mesh) of FMN and 5b are contoured at 3σ. (C) Overall
structure of NerA, with amino acids, FMN and 5b shown as in A. (D) Active site of NerA bound to ligand 5b with amino acids, FMN, 5b and omit maps
as shown as in B. (E) Overlay of apo-NerA (4JIC, grey) and NerA-5b complex. The loop β3 that shifts and adopts an anti-parallel β-strand in the
NerA-5b complex is indicated by dotted lines. The PEG molecule (yellow) in the active site of apo-NerA was replaced by 5b (purple) and acetate
(cyan) in the NerA-5b complex. (F) Orientation of 5b and FMN when XenA and NerA co-crystal structures were superimposed. The ﬁgure was gener-
ated using ccp4 mg.31
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one of the aromatic carbon atoms of phenylacrylic acid 5b
with the hydroxyl group of Y356. Crucially, this conformation
in NerA has increased the distance between Cβ of 5b and N5 of
FMN to 4.12 Å, and positions it at a non-optimal angle for
hydride attack. Therefore, this structure suggests that the
absence of activity with 5b could be due to ligand binding in
an orientation not favoured for hydride transfer. The presence
of the bulky side chain of Y27 in XenA would prevent substrate
binding in a NerA-like conformation due to a clash with the
aromatic ring of phenylacrylic acid 5b (N27 in NerA).
A sequence alignment of diﬀerent OYEs shows that Tyr27 is
conserved only among the ‘thermophilic-like’ subgroup
(Fig. 1), in which XenA, TOYE and YqjM belong. As TOYE is
inactive towards 5b, this suggests other residues and/or subtle
active site features must play a role in determining if an OYE
can bind 5b in an active conformation, particularly when
noting that GYE (active with 5b) is a member of the classical
subgroup of OYEs. Unfortunately, structural comparisons and/
or docking models of GYE (pdb code: 3WJS) and other classi-
cal OYEs with 5b were not possible (results not shown) as the
known low resolution X-ray crystal structure of GYE is lacking
its FMN cofactor.
Conclusions
OYEs are traditionally known to be inactive towards
α,β-unsaturated carboxylic acids or methyl esters unless there
is a second activating group conjugated to the double bond,
such as halides or a second acid/methyl ester functionality.2a
We demonstrated that selected ene reductases from the OYE
family are active towards α,β-unsaturated carboxylates 5a–c.
Analysis of the crystals structures XenA (active) and NerA (in-
active) with 5b highlighted subtle diﬀerences in active site and
conformation, determining their ability to catalyse the double
bond reduction.
Recent reports have highlighted the potential use OYEs in
the semi-synthetic biosynthesis of medicinally-important chi-
rally active profens, namely (R)-2.5b,32 Given that the pharmaco-
logically active form in most cases are (S)-profens, knowledge
of the substrate binding mode of precursor substrates could
lead to rationally-guided OYE active site mutagenesis studies
to generate (S)-selective profen products.
Experimental
General reagents and equipment
All solvents used were Fisher Optima LCMS grade, and formic
acid was Aristar grade from VWR. Compounds naproxen 1a,
profen precursors methyl 2-(6-methoxynaphthalen-2-yl)pro-
panoate 4a, 2-phenylacrylic acid 5b and 2-phenylpropionic
acid 1b, 2-(4-propylphenyl)acrylic acid 5c, 2-(4-propylphenyl)
propanoic acid 1c, and the Codexis glucose dehydrogenase
enzyme were kindly supplied by Dr Reddy’s Laboratories EU
via commercial suppliers. The concentration of nicotinamide
coenzymes (Melford) was determined by the extinction coeﬃ-
cient method (ε340 = 6220 M cm
−1). Steady-state kinetic ana-
lyses were performed on a Cary UV-50 Bio UV/Vis scanning
spectrophotometer using a quartz cuvette (1 mL; Hellma) with
a 1 cm path length. Anaerobic kinetics and biotransformation
reactions were set up and/or monitored within an anaerobic
glove box (Belle Technology Ltd) under a nitrogen atmosphere
(<5 ppm oxygen). Prior to anaerobic reactions, enzymes were
deoxygenated by passage through a BioRad 10DG column
equilibrated in anaerobic reaction buﬀer. Samples for single
molecule 1H NMR analysis were dissolved in CDCl3 and ana-
lysed on a Bruker 400 Hz NMR spectrophotometer. All spectra
were compared to authentic standards.
Compound synthesis
Synthesis of methyl 2-(6-methoxynaphthalen-2-yl)acrylate
3a. Thionylchloride (0.788 mL, 10.96 mmol) was added to a
stirred solution of (S)-2-(6-methoxynaphthalen-2-yl)propanoic
acid (0.5 g, 2.19 mmol) in toluene (50 mL) and the resultant
mixture refluxed for 4 h. The solution was cooled to 30 °C and
concentrated to 10 mL followed by addition of methanol
(30 mL) at 40 °C and stirring for an additional 2 h. The reac-
tion was cooled to room temperature and washed with water
(1 × 100 mL) and saturated sodium carbonate solution (2 ×
50 mL). The organic layer was dried over magnesium sulphate
and concentrated in vacuo to give the crude product as a yellow
oil. The crude product was purified by column chromato-
graphy (Hex : EtOAc 4 : 1, Rf = 0.45) to aﬀord the title com-
pound as white crystals (0.162 g, 30%). 1H NMR (400 MHz,
CDCl3) δ ppm: 7.88 (s, 1H, H-1), 7.44–7.79 (m, 2H), 7.52–7.55
(dd, 1H, J = 8, 4 Hz, H-5), 7.16–7.21 (m, 2H), 6.44 (d, 1H, J = 2
Hz, CvCH2), 6.02 (d, 1H, J = 2 Hz, CvCH2), 3.95 (s, 3H), 3.89
(s, 3H). 13C NMR (100 MHz, CDCl3) δ ppm: 167.5 (CvO), 158.1
(C-6), 141.2, 134.3, 131.9, 129.8, 128.5, 127.3, 126.6, 119.1,
105.6, 55.3 (OCH3), 52.2 (COOCH3). NMR traces are located in
the ESI (Fig. S15†).
Synthesis of 2-(6-methoxynaphthalen-2-yl)acrylic acid 5a.
Selenium dioxide (41.2 g; 0.37 mol) was added to a solution of
1-(6-methoxynaphthalen-2-yl)ethan-1-one (50.0 g; 0.25 mol) in
pyridine (213.5 mL) under N2 and the mixture heated to
110 °C for 18 h. The mixture was cooled to room temperature
and filtered, and the cake washed with EtOAc (100 mL). The
combined filtrates were concentrated in vacuo. 2 M NaOH
(4 volumes) was added to the residue, and the resultant solid
filtered. This solid was suspended in water (300 mL), the pH
adjusted to 1–2 with conc. HCl, and the solution extracted
with EtOAc (3 × 250 mL). The combined organic phases were
washed with water (250 mL), and evaporated. 2-(6-
Methoxynaphthalen-2-yl)-2-oxoacetic acid (44.0 g; 76%) was
recovered by filtration after trituration of the crude mass with
n-heptane (50 mL). 2-(6-Methoxynaphthalen-2-yl)-2-oxoacetic
acid (20.0 g; 87 mmol) was dissolved in anhydrous THF
(100 mL) under N2 and cooled to −30 °C. Methyl magnesium
chloride (1.0 M in THF; 132 mL; 0.13 mol) was added dropwise
whilst maintaining the temperature below −20 °C, and the
reaction stirred out for 2 h between −20 and −30 °C. The reac-
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tion was quenched by careful addition of conc. HCl (30 mL) at
0–5 °C, then water (80 mL) was added and the mixture stirred
out for 30 min, filtered, and the cake washed with EtOAc
(300 mL). The phases in the filtrate were separated, and the
aqueous phase extracted with EtOAc (100 mL). The combined
organic phases were washed with water (2 × 60 mL) and con-
centrated to ∼40 mL total volume. n-Heptane (80 mL) was
added and the mixture filtered. The cake was washed with
n-heptane (20 mL) and dried to give 2-(6-methoxynaphthalen-
2-yl)acrylic acid (14.0 g, 71%). 1H NMR (400 MHz, d6-DMSO)
∂ ppm: 7.9 (d, 1H, J = 1.2 Hz, H-1), 7.84 (d, 1H, J = 9.2 Hz), 7.79
(d, 1H, J = 8.8 Hz), 7.53 (d, 1H, J = 8.6 Hz, 1.8 Hz), 7.31 (d, 1H,
J = 2.4 Hz, H-5), 7.16 (dd, 1H, J = 8.8 Hz, 2.6 Hz, H-7), 6.26 (d,
1H, 2J = 1 Hz, CvCH2), 6.06 (d, 1H,
2J = 1 Hz, CvCH2), 3.86 (s,
3H, OCH3).
13C NMR (100 MHz, CDCl3) ∂ ppm: 168.0 (CvO),
157.6 (C-6), 141.4, 133.8, 131.7, 129.7, 127.9, 126.8, 126.5,
126.3, 125.5, 118.8, 105.6, 55.2 (OCH3). NMR traces are located
in the ESI (Fig. S15†).
Enzyme production and purification
The OYEs investigated were the following: (i) PETNR from
Enterobacter cloacae PB2, (ii) TOYE from Thermoanaerobacter
pseudethanolicus E39, (iii–iv) OYE2 and OYE3 from
Saccharomyces cerevisiae, (v) NerA from Agrobacterium radio-
bacter, (vi) XenA from Pseudomonas putida, (vii) GYE from
Gluconobacter oxydans and (viii) LeOPR1 from Solanum lycoper-
sicum.33 The flavin-independent double bond reductase
NtDBR from Nicotiana tabacum was also used in this study.13
The enzymes XenA, NerA and LeOPR1 were cloned into
plasmid pET21a, while OYE2, OYE3, TOYE and NtDBR were
expressed in pET21b. GYE was supplied in a pET28b plasmid,
while the C-terminally His8-tagged PETNR gene
34 was cloned
into pBluescript SK+ (Stratagene) under the control of a native
lac promoter.35 All constructs contained a C-terminal His6/8-
tag, and were expressed in the Escherichia coli strain BL21
(DE3) except for PETNR and TOYE which were expressed in
JM109 and Arctic Express strains, respectively.
All ene-reductases were produced and purified using the
same general protocol. Starter cultures (5 mL and 20 mL) were
produced overnight in lysogeny broth (LB) containing glucose
(0.2%) and ampicillin (100 μg mL−1; 15 μg mL−1 kanamycin
for GYE). The starter cultures were used to inoculate terrific
broth (TB; 12 × 1 L per enzyme) containing glucose (2%), and
incubated at 37 °C and 190 rpm until mid log phase (OD
600 nm ∼ 0.5). Recombinant protein expression was induced
by the addition of IPTG (10 μM), followed by incubation over-
night at 25 °C (18 °C for TOYE), at 190 rpm. Cells were har-
vested by centrifugation for 10 min at 5000g at 4 °C, and the
supernatant discarded. The cell pellets were frozen in liquid
nitrogen and stored at −80 °C.
The cells were resuspended in lysis buﬀer (50 mM KH2PO4/
K2HPO4 pH 8.0) containing 1× protease inhibitor cocktail
(Roche) and DNase (10 μg mL−1) and lysozyme (10 μg mL−1).
Excess free FMN was added to the OYE cell slurries to increase
the degree of flavination of the enzymes. The cells were
lysed using a sonicator (Bandelin) with a probe set at 40%
amplitude with cycles of 10 s ON and 10 s OFF for 12 min. The
lysed cells were centrifuged at 18 000g for 1 h and the super-
natant was passed through a 0.2 micron filter. NaCl (300 mM)
and imidazole (10 mM) were added, and the extracts were
passaged through Nickel Sepharose aﬃnity column (20 mL),
pre-equilibrated in equilibration buﬀer (50 mM KH2PO4/
K2HPO4 pH 8.0, 300 mM NaCl, 10 mM imidazole). The
column was washed with wash buﬀer (50 mM KH2PO4/
K2HPO4 pH 8.0, 300 mM NaCl, 20 mM imidazole; 200 mL) fol-
lowed by elution buﬀer (50 mM KH2PO4/K2HPO4 pH 8.0,
300 mM NaCl, 300 mM imidazole, 150 mL). In some cases an
additional nickel Sepharose purification step was performed,
as detailed above, to increase the protein purity. Protein purity
was assessed by SDS-PAGE, using 10–12% Mini-PROTEAN®
TGX Stain-Free™ gels and Precision Plus protein unstained
markers (BioRad) according to the manufacturer’s instructions.
Purified protein was desalted and concentrated using Vivaspin
tubes (10 000 MW cut-oﬀ ). Protein concentrations of each OYE
was determined using the extinction coeﬃcient method with
the following values (M cm−1): PETNR ε464 = 11 300; TOYE ε456
= 11 300; OYE2 ε462 = 10 600; OYE3 ε464 = 10 600; GYE ε450 =
11 300; XenA ε450 = 11 300; NerA ε450 = 11 300 and LeOPR1 ε450 =
11 300. Enzyme NtDBR protein concentration was determined
by the Bradford method.36 Aliquots of enzyme were flash frozen
in liquid nitrogen and stored in fractions at −80 °C.
Steady state kinetics
Standard ene-reduction reactions (1 mL) were performed an-
aerobically in buﬀer (50 mM K2HPO4/KH2PO4) containing
alkene (1 mM) and NADPH (100 μM) at 25 °C at the reported
pH optimum for each enzyme. The reaction was initiated by
addition of the oxidative substrate and the loss of NADPH was
monitored continuously at OD 340 nm. The substrates tested
were ketoisophorone, 2-cyclohexen-1-one and nitrocyclo-
hexene, and the results were compared to literature values
where available. Initial rates were determined using Cary WinUV
software and expressed as specific activity (μmol min−1 mg−1).
Biotransformation reactions
Biotransformation reactions (1.0 mL) were performed anaero-
bically in buﬀer (K2HPO4/KH2PO4 pH 7.5) containing the
alkene (5 mM in 100% DMF), NADP+ (10 μM), D-glucose
(15 mM), glucose dehydrogenase (GDH; 10 U) and enzyme
(2 μM). Reactions were shaken at 30 °C for 24 h at 130 rpm
and terminated by extraction with ethyl acetate (0.9 mL) for
achiral GC analysis, or diluted 10-fold with acetonitrile for chiral
HPLC analysis. Scaled up reactions (50 mg) were performed
using the same molarities as standard reactions and were incu-
bated for 48 h. All biotransformation reactions were performed
in at least duplicates, and the results are averages of the data.
Analysis of biotransformations
Carboxylic acids 1a–b and 5a–b were converted to methyl
esters using trimethylsilyl diazomethane prior to analysis. The
biotransformation mixture (500 μL) was acidified to pH 5
using 1 M HCl and extracted into ethyl acetate (500 μL).
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Methanol (50 μL) was then added followed by trimethylsilyl
diazomethane (10 μL). The mixtures were incubated for
20 min at 25 °C then quenched by the addition of glacial
acetic acid (5 μL).
The conversions and yields were determined by GC (Agilent
Technologies 7890A system with FID detector) using limonene
as an internal standard (0.5%): ZB-semi volatiles column
(30 m; 0.25 mm; 0.25 μm film thickness; Phenomenex); injec-
tor 220 °C, split ratio of 20 : 1; 1 μL injection, 5 psi, flow 1 mL
min−1 (helium); oven: 80 °C (2 min), 30 °C min−1 to 300 °C,
hold (3 min). Quantitative analysis was carried using cali-
bration curves.
Chiral analysis of the products was performed by
HPLC (Agilent 1100 m with diode array detection, λ 220 nm)
and compared to authentic standards of enantiomers.
Compounds 1a and 5a: Chiralpak AS-RH (150 × 4.6 mm ID),
20 °C, MeCN : H2O (40 : 60), 0.8 mL min
−1, Rt: (S)-1a 4.1 min;
(R)-1a 4.6 min. Compound 5b: Chiralpak AD-H (150 × 4.6 mm
ID), 20 °C, hexane : isopropanol (95 : 5), 1 mL min−1, Rt: (R)-1b
8.1 min; (S)-1b 9.2 min. Preparative HPLC purification of 1a
was performed using Phenomenex Luna C18 column (5 μ ×
21.2 × 250 mm) at 15 mL min−1 using a gradient of
MeCN : H2O 10 : 90 to 50 : 50 over 15 min.
1H NMR analysis is
presented in ESI Fig. S10–S13.†
UHPLC-MS analysis was performed using a Dionex U3000
RSLC system equipped with a Thermo-Fisher Q-Exactive Plus
detector, 5 μL injection. All analysis was carried out in positive
ionisation mode using Thermo Fisher Accucore C18 column
(2.6 μm × 2.1 mm × 100 mm); average peak 6 s; 0.5 mL min−1;
mobile phase: A (95% H2O 5% MeOH 0.1% formic acid) and
B (95% MeOH 5% H2O 0.1% formic acid); gradient A : B: 95 : 5
(hold 2 min) to 5 : 95 over 3 min (hold 2 min), to 95 : 5 over
1 min (hold 2 min).
Protein crystallography
XenA and NerA were concentrated to 15 mg mL−1 and 23
mg mL−1 respectively. Crystallisation trials were set up using a
Mosquito robot (TTP Labtech) by dispensing 200 nL of both
protein and crystallisation solution. XenA and NerA crystals
were obtained in crystallisation solution A (0.2 M sodium
iodide, 0.1 M Bis–Tris propane pH 7.5 and 20% (w/v) PEG
3350) and B (0.1 M sodium acetate, 1 M lithium chloride, 30%
(w/v) PEG 6000), respectively. Crystals were incubated with
25 mM 5b dissolved in their respective mother liquors and
supplemented with 20% glycerol for 10 min. Crystals were
cryo-cooled in liquid nitrogen prior to data collection.
Structure solution for XenA and NerA
X-ray diﬀraction data were collected at Diamond Light Source
beamlines I03 and I24. The NerA dataset was processed using
the automated data reduction pipeline in xia237 using XDS41 to
1.58 Å. The XenA dataset was manually processed using
MOSFLM38 and Aimless,39 as implemented in ccp4,40 to 2.2 Å.
The 5b-bound structures of XenA and NerA were solved by
molecular replacement using XenA (modified 5bPM) and NerA
(modified 4JIC) coordinates, respectively, as search models in
Phaser.41 The models were built and refined using Phenix.42
The structures were completed by iterative cycles of manual
model building in Coot43 and refinement using phenix.
refine.44 The structures were validated using PDB_REDO45 and
Molprobity.46 The data summary and refinement parameters
are listed in Table 2. The atomic coordinates and structure
factors have been deposited in the Protein Data Bank (PDB
codes 5N6Q (XenA) and 5N6G (NerA)).
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